Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.

Leukemia & lymphoma - 1 Apr 2018

Andritsos Leslie A, Grieselhuber Nicole R, Anghelina Mirela, Rogers Kerry A, Roychowdhury Sameek, Reeser Julie W, Timmers Cynthia D, Freud Aharon G, Blachly James S, Lucas David M, Lozanski Gerard, Jones Jeffrey A, Williams Katie, Oakes Christopher, Jones Dan, Grever Michael R

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, Immunoglobulin Heavy Chain
Share to Immunoglobulin Heavy Chains
Share to Immunoglobulin Variable Region

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Hairy Cell

Share to MAP Kinase Kinase 1

Share to Protein Kinase Inhibitors

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 28918710
DOI: 10.1080/10428194.2017.1365853
PMCID: PMC7664305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.PMID 28918710Read ↗

Targetable Mutations in BRAF V600E–Negative Hairy-Cell LeukemiaSemantic proximity Read ↗

BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials.Semantic proximity Read ↗

Non-V600E BRAF mutations and treatment for hairy cell leukemia.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.Semantic proximity Read ↗

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.Semantic proximity Read ↗

Transformation of IGHV4-34+ hairy cell leukaemia-variant with U2AF1 mutation into a clonally-related high grade B-cell lymphoma responding to immunochemotherapy.Semantic proximity Read ↗

Update on the biology and treatment options for hairy cell leukemia.Semantic proximity Read ↗

Hairy Cell Leukemia Masquerading as CD5+ Lymphoproliferative Disease: The Importance of BRAF V600E Testing in Diagnosis and Treatment.Semantic proximity Read ↗

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Non-canonical BRAF variants and rearrangements in hairy cell leukemia.Semantic proximity Read ↗

Genomics of Hairy Cell LeukemiaSemantic proximity Read ↗

Hairy cell leukemia: Past, present and future.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.